These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 26548937)

  • 1. Toxicity and adverse effects of everolimus in the treatment of advanced nonsmall cell lung cancer pretreated with chemotherapy--Chinese experiences.
    Ju Y; Hu Y; Sun S; Wang J; Jiao S
    Indian J Cancer; 2015 Nov; 52 Suppl 1():e32-6. PubMed ID: 26548937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors.
    Soria JC; Shepherd FA; Douillard JY; Wolf J; Giaccone G; Crino L; Cappuzzo F; Sharma S; Gross SH; Dimitrijevic S; Di Scala L; Gardner H; Nogova L; Papadimitrakopoulou V
    Ann Oncol; 2009 Oct; 20(10):1674-81. PubMed ID: 19549709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Miracle Mouthwash plus Hydrocortisone Versus Prednisolone Mouth Rinses as Prophylaxis for Everolimus-Associated Stomatitis: A Randomized Phase II Study.
    Jones VE; McIntyre KJ; Paul D; Wilks ST; Ondreyco SM; Sedlacek S; Melnyk A; Oommen SP; Wang Y; Peck SR; O'Shaughnessy JA
    Oncologist; 2019 Sep; 24(9):1153-1158. PubMed ID: 30833486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Everolimus in combination with pemetrexed in patients with advanced non-small cell lung cancer previously treated with chemotherapy: a phase I study using a novel, adaptive Bayesian dose-escalation model.
    Vansteenkiste J; Solomon B; Boyer M; Wolf J; Miller N; Di Scala L; Pylvaenaeinen I; Petrovic K; Dimitrijevic S; Anrys B; Laack E
    J Thorac Oncol; 2011 Dec; 6(12):2120-9. PubMed ID: 21900840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer.
    Ramalingam SS; Harvey RD; Saba N; Owonikoko TK; Kauh J; Shin DM; Sun SY; Strychor S; Tighiouart M; Egorin MJ; Fu H; Khuri FR
    Cancer; 2010 Aug; 116(16):3903-9. PubMed ID: 20564143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of everolimus-erlotinib in previously treated patients with advanced non-small-cell lung cancer.
    Besse B; Leighl N; Bennouna J; Papadimitrakopoulou VA; Blais N; Traynor AM; Soria JC; Gogov S; Miller N; Jehl V; Johnson BE
    Ann Oncol; 2014 Feb; 25(2):409-15. PubMed ID: 24368400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer.
    Papadimitrakopoulou VA; Soria JC; Jappe A; Jehl V; Klimovsky J; Johnson BE
    J Thorac Oncol; 2012 Oct; 7(10):1594-601. PubMed ID: 22968184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of docetaxel in combination with everolimus for second- or third-line therapy of advanced non-small-cell lung cancer.
    Ramalingam SS; Owonikoko TK; Behera M; Subramanian J; Saba NF; Kono SA; Gal AA; Sica G; Harvey RD; Chen Z; Klass CM; Shin DM; Fu H; Sun SY; Govindan R; Khuri FR
    J Thorac Oncol; 2013 Mar; 8(3):369-72. PubMed ID: 23407561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non-small cell lung cancer.
    Eberhardt WE; Mitchell P; Schiller JH; Brown MP; Thomas M; Mills G; Jehl V; Urva SR; De Leo JJ; Gogov S; Papadimitrakopoulou V
    Invest New Drugs; 2014 Feb; 32(1):123-34. PubMed ID: 23579358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer.
    Milton DT; Riely GJ; Azzoli CG; Gomez JE; Heelan RT; Kris MG; Krug LM; Pao W; Pizzo B; Rizvi NA; Miller VA
    Cancer; 2007 Aug; 110(3):599-605. PubMed ID: 17577220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer.
    Powles T; Wheater M; Din O; Geldart T; Boleti E; Stockdale A; Sundar S; Robinson A; Ahmed I; Wimalasingham A; Burke W; Sarker SJ; Hussain S; Ralph C
    Eur Urol; 2016 Mar; 69(3):450-6. PubMed ID: 26364551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients.
    Herbst RS
    Semin Oncol; 2003 Feb; 30(1 Suppl 1):30-8. PubMed ID: 12644982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy.
    Rugo HS; Hortobagyi GN; Yao J; Pavel M; Ravaud A; Franz D; Ringeisen F; Gallo J; Rouyrre N; Anak O; Motzer R
    Ann Oncol; 2016 Mar; 27(3):519-25. PubMed ID: 26759276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crizotinib in Chinese Patients with ROS1-Rearranged Advanced Non‒Small-Cell Lung Cancer in Routine Clinical Practice.
    Liu C; Yu H; Chang J; Chen H; Li Y; Zhao W; Zhao K; Zhu Z; Sun S; Fan M; Wang J
    Target Oncol; 2019 Jun; 14(3):315-323. PubMed ID: 30976989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer.
    Price KA; Azzoli CG; Krug LM; Pietanza MC; Rizvi NA; Pao W; Kris MG; Riely GJ; Heelan RT; Arcila ME; Miller VA
    J Thorac Oncol; 2010 Oct; 5(10):1623-9. PubMed ID: 20871262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naïve Advanced Pancreatic Neuroendocrine Tumors.
    Salazar R; Garcia-Carbonero R; Libutti SK; Hendifar AE; Custodio A; Guimbaud R; Lombard-Bohas C; Ricci S; Klümpen HJ; Capdevila J; Reed N; Walenkamp A; Grande E; Safina S; Meyer T; Kong O; Salomon H; Tavorath R; Yao JC
    Oncologist; 2018 Jul; 23(7):766-e90. PubMed ID: 29242283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Response to Everolimus of EGFR-Mutation-Positive NSCLC With Primary Resistance to EGFR TKIs.
    Matsuoka H; Kaneda H; Sakai K; Koyama A; Nishio K; Nakagawa K
    Clin Lung Cancer; 2017 Jan; 18(1):e85-e87. PubMed ID: 28341110
    [No Abstract]   [Full Text] [Related]  

  • 18. Rationale for a phase I trial of erlotinib and the mammalian target of rapamycin inhibitor everolimus (RAD001) for patients with relapsed non small cell lung cancer.
    Johnson BE; Jackman D; Jänne PA
    Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4628-31. PubMed ID: 17671154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non-Small Cell Lung Cancer.
    Owonikoko TK; Ramalingam SS; Miller DL; Force SD; Sica GL; Mendel J; Chen Z; Rogatko A; Tighiouart M; Harvey RD; Kim S; Saba NF; Pickens A; Behera M; Fu RW; Rossi MR; Auffermann WF; Torres WE; Bechara R; Deng X; Sun SY; Fu H; Gal AA; Khuri FR
    Clin Cancer Res; 2015 Apr; 21(8):1859-68. PubMed ID: 25673697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I/II study of docetaxel combined with resminostat, an oral hydroxamic acid HDAC inhibitor, for advanced non-small cell lung cancer in patients previously treated with platinum-based chemotherapy.
    Tambo Y; Hosomi Y; Sakai H; Nogami N; Atagi S; Sasaki Y; Kato T; Takahashi T; Seto T; Maemondo M; Nokihara H; Koyama R; Nakagawa K; Kawaguchi T; Okamura Y; Nakamura O; Nishio M; Tamura T
    Invest New Drugs; 2017 Apr; 35(2):217-226. PubMed ID: 28138828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.